Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23 | Free Publication Certificate
NAAS Rating: 5.23 new

Vol. 7, Issue 9 (2018)

Prospects for the use of exenatide in the correction of experimental diabetic cardiomyopathies

TI Vlasiuk and OYa Zhurakivska
The purpose of this study is to shine a light on the structural changes of atrial cardiomyocytes of rats with streptozotocin-induced diabetes mellitus (DM) and the course of its treatment. DM was modeled by a single intraperitoneal administration of streptozotocin (dilutedin 0.1 М ofcitrate buffer with the pH of 4.5 at a dose of 6 mg per 100 grams ofbodymass). Antidiabetic therapy was performed with exenatide starting from the 14th day of the experiment. It is established that daily exenatide injections lead to a good glycemic control only at the initial stage of the experiment.However, its use as a monotherapy is not justified for correction of diabetes due to poor glycemic control and levels of glycosylated hemoglobin during later terms of the experiment. Using exenatide in experiment, we did not observe the repair of the structure of atrial cardiomyocytes in the late stages of experimental streptozotocin-induced DM.
Pages: 35-40  |  1048 Views  58 Downloads

The Pharma Innovation Journal
How to cite this article:
TI Vlasiuk, OYa Zhurakivska. Prospects for the use of exenatide in the correction of experimental diabetic cardiomyopathies. Pharma Innovation 2018;7(9):35-40.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal

Call for book chapter
The Pharma Innovation Journal